You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,319,097


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,319,097
Title: Pharmaceutical agents
Abstract:The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxy-carbonyl)amino-1-methylindol-3-yl-methyl]-3-methox ybenzoyl]-2-methylbenzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyll-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.
Inventor(s): Holohan; James J. (Macclesfield, GB2), Edwards; Ieuan J. (Congleton, GB2)
Assignee: Imperial Chemical Industries PLC (Millbank, GB2)
Application Number:07/805,421
Patent Claims: 1. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3methoxyb enzoyl]-2-methylbenzenesulphonamide which physical form is a monohydrate of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzene-sulphonamide which is crystalline, has an infra-red spectrum (0.5% in KBr) having sharp peaks at 3560, 1690, 1660, 1540, 1440, 1165, 880 and 858cm.sup.-1, and an X-ray powder diffraction pattern having peaks at 2.theta.=10.0.degree., 11.2.degree., 14.6.degree., 19.8.degree.and 23.0.degree..

2. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3methoxyb enzoyl]-2-methylbenzenesulphonamide, as claimed in claim 1, which physical form is a monohydrate of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide which is crystalline, has an infra-red spectrum (0.5% in KBr) having sharp peaks at 3560, 1690, 1660, 1540, 1440, 1165, 880 and 858cm.sup.-1 ; an X-ray powder diffraction pattern having peaks at 2.theta.=10.0.degree., 11.2.degree., 14.6.degree., 19.8.degree. and 23.0.degree.; and a melting point in the range from 145.degree. to 155.degree. C.

3. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide as claimed in claim 1 which is substantially free of any other physical forms.

4. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide as claimed in claim 1 which is substantially free of other crystalline forms.

5. A process for preparing a physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3yl-methyl]-3-methoxyb enzoyl]-2-methylbenzenesulphonamide which physical form has an infra-red spectrum (0.5% in KBr) having sharp peaks at 1690, 1530, 1490, 1420, 1155, 1060, 862 and 550cm.sup.-1 and a melting point between 115.degree. and 140.degree. C., which comprises spray drying a solution of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide.

6. A process as claimed in claim 5, in which an aqueous acetone solution is used.

7. A solution of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide in aqueous acetone.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.